Abstract:Contrast media induce various factors that may increase vasoconstriction and decrease vasodilatation in the renal medulla, leading to hypoxia and acute tubular necrosis known as contrast-induced nephropathy (CIN) that tends to occur in diabetics and patients with preexisting renal insufficiency. Contrast media inhibit mitochondrial enzyme activities and subsequently increase adenosine through hydrolysis of ATP. Both catabolism of adenosine and medullary hypoxia generate reactive oxygen species (ROS) that scavenge nitric oxide (NO). Released along with endothelin and prostaglandin from endothelial cells exposed to contrast media, adenosine activates the A1 receptor that mainly constricts afferent arteriole at the glomerulus but not the medullary vasculature. Adenosine also activates the A2 receptor that increases NO production, leading to medullary vasodilatation which is induced by activation of endothelin-B receptor and G-protein coupled E-prostanoid receptor 2, and 4 of prostaglandin PGE2 respectively as well. Conversely medullary vasoconstriction is mediated by activating endothelin-A receptor and G-protein coupled E-prostanoid receptor 1, and 3 of prostaglandin PGE2 respectively. The osmotic load of contrast media increases interstitial pressure and sodium transport and thus oxygen consumption. Risking hypoxia, increased medullary oxygen consumption may also result from stimulating Na+–K+-ATPase activity by endothelin-A receptor. N-acetylcysteine (NAC) scavenges ROS and therefore preserves NO that not only dilates medullary vasculature but also reduces sodium reabsorption and oxygen consumption, tipping the balance against medullary vasoconstriction, hypoxia, and thus CIN. While prostacyclin and its analog, iloprost, prevent CIN by inducing medullary vasodilatation, atrial natriuretic peptide (ANP) may do so by inhibiting renin secretion.

The pathogenesis and preventive measures of contrast-induced nephropathy

[Early prevention progress of contrast induced nephropathy]

Risk factors and recent advances in the prevention of contrast - induced nephropathy

Contrast-Induced Nephropathy: A Review of Mechanisms and Risks

The Research Progress of Contrast Media Induced Nephropathy

Clinical Study of Contrast-induced Nephropathy in Inpatients in Cardiology Department After Coronaryartery Intervention

The Value of Cystatin C in renal Dysfunction Related to Percutaneous Coronary Intervention

Clinical study of contrast induced nephropathy in patients undergoing coronary intervention.

Contrast-induced nephropathy in interventional cardiology

Contrast-induced Nephropathy in CT: Incidence, Risk Factors and Strategies for Prevention.

Contrast Induced Nephropathy: an Ignored Important Complication in Interventional Radiology

Evaluation and prevention of patients at high risk for contrast-induced nephropathy

Epidemiology of contrast-induced nephropathy after computerized tomography

Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches

Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Contrast-Induced Nephropathy

A Prospective Study on the Risk of Contrast Induced Nephropathy in the Patients Who Underwent Contrast-Enhanced CT Examination

Clinical Survey on Contrast-Induced Nephropathy after Coronary Angiography.

A Multi-Center Clinical Study of Contrast-Induced Nephropathy in Inpatients in Cardiology Department after Coronary Artery Intervention

Pathophysiology of contrast-induced nephropathy.

Contrast-induced nephropathy in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention

The Molecular Mechanism of Contrast-Induced Nephropathy (CIN) and Its Link to in Vitro Studies on Iodinated Contrast Media (CM)